MedTrace Logo

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

NCT02933710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-04-25

No results posted yet for this study

Summary

The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation.

Primary objective:

* To describe the safety profile of the first dose of IMOJEV® administered under routine health care visit as primary vaccination or as booster.

Conditions

  • Japanese Encephalitis

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur Inc.

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-21
Primary Completion
2018-10-18
Completion
2018-10-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933710 on ClinicalTrials.gov